OIM
Oracle Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-535,558
| Closed | -$4.03M | – | 12 |
|
|
2024
Q4 | $4.03M | Hold |
535,558
| – | – | 2.19% | 6 |
|
|
2024
Q3 | $4.07M | Hold |
535,558
| – | – | 2.44% | 6 |
|
|
2024
Q2 | $3.31M | Hold |
535,558
| – | – | 3.09% | 7 |
|
|
2024
Q1 | $2.72M | Hold |
535,558
| – | – | 1.81% | 9 |
|
|
2023
Q4 | $3.21M | Sell |
535,558
-19,964
| -4% | -$120K | 1.95% | 8 |
|
|
2023
Q3 | $3.93M | Hold |
555,522
| – | – | 1.21% | 4 |
|
|
2023
Q2 | $3.91M | Hold |
555,522
| – | – | 2.88% | 8 |
|
|
2023
Q1 | $4.63M | Sell |
555,522
-29,672
| -5% | -$247K | 4.48% | 8 |
|
|
2022
Q4 | $6.72M | Sell |
585,194
-50,000
| -8% | -$574K | 5.6% | 5 |
|
|
2022
Q3 | $8M | Buy |
635,194
+31,200
| +5% | +$393K | 4.55% | 7 |
|
|
2022
Q2 | $6.39M | Sell |
603,994
-1,116,739
| -65% | -$11.8M | 1.94% | 8 |
|
|
2022
Q1 | $28M | Buy |
1,720,733
+50,000
| +3% | +$813K | 5.53% | 4 |
|
|
2021
Q4 | $23.1M | Sell |
1,670,733
-250,000
| -13% | -$3.46M | 3.29% | 8 |
|
|
2021
Q3 | $27.6M | Hold |
1,920,733
| – | – | 3.44% | 8 |
|
|
2021
Q2 | $30.4M | Sell |
1,920,733
-446,937
| -19% | -$7.07M | 4.19% | 9 |
|
|
2021
Q1 | $24.1M | Sell |
2,367,670
-613,200
| -21% | -$6.24M | 3.61% | 9 |
|
|
2020
Q4 | $22.2M | Buy |
2,980,870
+455,013
| +18% | +$3.39M | 2.78% | 8 |
|
|
2020
Q3 | $8.68M | Buy |
2,525,857
+525,857
| +26% | +$1.81M | 1.14% | 9 |
|
|
2020
Q2 | $9.53M | Buy |
+2,000,000
| New | +$9.53M | 1.21% | 8 |
|